The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark ; volume:13 ; number:3 ; day:21 ; month:2 ; year:2022 ; pages:489-503 ; date:3.2022
Diabetes therapy ; 13, Heft 3 (21.2.2022), 489-503, 3.2022
- Creator
-
Ehlers, Lars H.
Lamotte, Mark
Ramos, Mafalda C.
Sandgaard, Susanne
Holmgaard, Pia
Kristensen, Malene M.
Ejskjaer, Niels
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-022-01221-3
- URN
-
urn:nbn:de:101:1-2022061118471656971712
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ehlers, Lars H.
- Lamotte, Mark
- Ramos, Mafalda C.
- Sandgaard, Susanne
- Holmgaard, Pia
- Kristensen, Malene M.
- Ejskjaer, Niels
- SpringerLink (Online service)
Other Objects (12)
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
Empagliflozin/Metformin: Nutzenbewertung gemäß § 35a SGB V
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Semaglutide
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
Empagliflozin/Metformin: Nutzenbewertung gemäß § 35a SGB V
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Semaglutide
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
Empagliflozin/Metformin: Nutzenbewertung gemäß § 35a SGB V
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Semaglutide
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects